Reimagining Medicine Q2 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Novartis pipeline in Phase 1 Solid tumors Code Name 177Lu-NeoB AAA603 AAA817 225 AC-PSMA-617 DFF332 DFF332 IAG933 IAG933 KFA115 KFA115 MGY825 MGY825 NZV930 NZV930 QEQ278 QEQ278 Immunology Code MHV370 Conclusions Mechanism Radioligand therapy target GRPR Radioligand therapy target PSMA HIF2A inhibitor Novel immunomodulatory Agent CD73 antagonist Indication(s) Multiple solid tumors Metastatic castration-resistant prostate cancer Renal cell carcinoma Mesothelioma Solid tumors NSCLC Solid tumors NKG2D/-L pathway modulator Solid tumors Name MHV370 Mechanism Indication(s) TLR7, TLR8 Antagonist Systemic lupus erythematosus Neuroscience Code NIO752 Name Mechanism NIO752 Tau antagonist Hematology Name Code DFV890 DFV890 HDM201 HDM201 (combos) MDM2 inhibitor JBH492 JBH492 MBG453 sabatolimab TIM3 antagonist MIK665 PIT565 VAY736 MIK665 MCL1 inhibitor PIT565 ianalumab + ibrutinib BAFF-R inhibitor Indication(s) Alzheimer's disease Progressive supranuclear palsy Mechanism NLRP3 inhibitor Indication(s) Low risk myelodysplastic syndrome Hematological malignancy Hematological malignancy Low risk myelodysplastic syndrome Hematological malignancies B-cell malignancies Hematological malignancy (combo) Diffuse large B-cell lymphoma Cancers Adult ALL VOB560 YTB323 VOB560 rapcabtagene autoleucel CD19 CAR-T 32 Investor Relations | Q2 2023 Results Appendix Innovation: Clinical trials Cardiovascular Code XXB750 References Abbreviations INNOVATION 17 lead indications Name XXB750 Mechanism NPR1 agonist Indication(s) Heart failure Others Code IB&GH EDI048 EYU688 Name EDI048 EYU688 INE963 INE963 Mechanism CpPI(4)K inhibitor NS4B inhibitor Indication(s) Cryptosporidiosis Dengue Malaria, uncomplicated Lead indication NOVARTIS | Reimagining Medicine

View entire presentation